• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by RxSight Inc.

    11/14/24 5:46:12 PM ET
    $RXST
    Ophthalmic Goods
    Health Care
    Get the next $RXST alert in real time by email
    SC 13G/A 1 tm2427451d25_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)*

     

    RxSIGHT, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    78349D107

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨   Rule 13d-1(b)

    x  Rule 13d-1(c)

    ¨   Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 78349D107

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Management, L.P.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

    (b)       ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0

     

    6

    SHARED VOTING POWER

     

    3,916,825

     

    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    3,916,825

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,916,825

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.9%

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, PN

     

     

     

     

     

    CUSIP No. 78349D107

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Peter Kolchinsky

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

    (b)       ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0

     

    6

    SHARED VOTING POWER

     

    3,916,825

     

    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    3,916,825

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,916,825

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.9%

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, IN

     

     

     

     

     

    CUSIP No. 78349D107

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Rajeev Shah

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

    (b)       ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0

     

    6

    SHARED VOTING POWER

     

    3,916,825

     

    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    3,916,825

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,916,825

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.9%

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, IN

     

     

     

     

     

    CUSIP No. 78349D107

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Healthcare Fund, L.P.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

    (b)       ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0

     

    6

    SHARED VOTING POWER

     

    3,702,967

     

    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    3,702,967

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,702,967

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.3%

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     

     

     

     

     

    Item 1(a). Name of Issuer:

     

    RxSIGHT, Inc. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    100 Columbia Street, Aliso Viejo, California 92656

     

    Item 2(a).Names of Persons Filing:

     

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

     

    RA Capital Management, L.P. (“RA Capital”)

    Peter Kolchinsky

    Rajeev Shah

    RA Capital Healthcare Fund, L.P. (the “Fund”)

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    The address of the principal business office of each of the Reporting Persons is:

     

    c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116

     

    Item 2(c).Citizenship:

     

    RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United States citizens.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.001 per share (“Common Stock”)

     

    Item 2(e).CUSIP Number:

     

    78349D107

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4.Ownership.

     

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G/A. The ownership percentages reported are based on 39,682,804 shares of Common Stock, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 5, 2024.

     

    The Fund directly holds 3,702,967 shares. A separately managed account (the “Account”) holds 213,858 shares.

     

     

     

     

    RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and the Account and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the “Act”), of any securities of the Issuer held by the Fund and the Account. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolio, including the shares of the Issuer’s Common Stock reported herein.  Because the Fund has divested itself of voting and investment power over the reported securities they hold and may not revoke that delegation on less than 61 days’ notice, the Fund disclaims beneficial ownership of the securities they hold for purposes of Section 13(d) of the Act and therefore disclaim any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G/A Statement (the “Statement”) other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of the Statement shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    Exhibit List

     

    Exhibit 1: Joint Filing Agreement

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: November 14, 2024

     

    RA CAPITAL MANAGEMENT, L.P.

     

    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Authorized Signatory  

     

    PETER KOLCHINSKY

     

    /s/ Peter Kolchinsky  

     

    RAJEEV SHAH

     

    /s/ Rajeev Shah  

     

    RA CAPITAL HEALTHCARE FUND, L.P.

     

    By: RA Capital Healthcare Fund GP, LLC  
    Its: General Partner  
         
    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Manager  

     

     

     

    Get the next $RXST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RXST

    DatePrice TargetRatingAnalyst
    5/19/2025$25.00Equal Weight → Overweight
    Wells Fargo
    4/15/2025$18.00Neutral
    Piper Sandler
    4/9/2025$16.00Buy → Neutral
    UBS
    4/4/2025$40.00 → $17.00Overweight → Underweight
    Analyst
    4/3/2025$36.00 → $22.00Buy → Underperform
    BofA Securities
    12/20/2024$65.00 → $40.00Buy → Hold
    Stifel
    12/11/2024$56.00 → $42.00Overweight → Equal Weight
    Wells Fargo
    12/6/2024$52.00Buy
    UBS
    More analyst ratings

    $RXST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Corley Jesse Anderson bought $100,004 worth of shares (3,210 units at $31.15) (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      1/17/25 7:08:42 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Director Corley Jesse Anderson bought $1,014,570 worth of shares (22,476 units at $45.14), increasing direct ownership by 18% to 38,438 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      11/14/24 7:14:14 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Tammenoms Bakker Juliet bought $305,456 worth of shares (5,000 units at $61.09), increasing direct ownership by 17% to 34,840 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      5/21/24 4:11:17 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Leadership Updates

    Live Leadership Updates

    See more
    • Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

      Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

      5/30/24 4:00:00 AM ET
      $ALC
      $NARI
      $OCS
      $RXST
      Ophthalmic Goods
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • RxSight, Inc. Appoints Dr. Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors

      ALISO VIEJO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced the appointment of Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors. "We are very excited to continue to strengthen the RxSight Board of Directors with the additions of Dr. Fountain and Ms. Maniar. Their diverse healthcare leadership experience will support the strategic advancement of the company through its next chapter of growth," said J. Andy Corley, Chair of the Board of Directors. "We look forward to their respective contributions as the RxSight® Lig

      1/4/22 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • RxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology Forum

      ALISO VIEJO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Stifel Virtual Ophthalmology Forum. RxSight's management is scheduled to participate in a fireside chat on Tuesday, May 27, 2025, at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. A live and archived webcast of the presentation will be available on the Company's investor relations website at https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providin

      5/20/25 4:10:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. Reports First Quarter 2025 Financial Results

      ALISO VIEJO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2025. Key Quarterly Highlights Reported first quarter 2025 revenue of $37.9 million, an increase of 28% compared to the first quarter of 2024, reflecting: The sale of 27,579 Light Adjustable Lenses (LAL®/LAL+®), representing a 36% increase in procedure volume compared to the first quarter of 2024;The sale of 73 Light Delivery Devices (LDD™s), bringing the installed base to 1,044 LDDs as of M

      5/7/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. to Present at the Bank of America Healthcare Conference

      ALISO VIEJO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference in Las Vegas. RxSight's management is scheduled to present on Wednesday, May 14, 2025, at 3:40 p.m. Pacific Time / 6:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized visio

      4/30/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Financials

    Live finance-specific insights

    See more
    • RxSight, Inc. Reports First Quarter 2025 Financial Results

      ALISO VIEJO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2025. Key Quarterly Highlights Reported first quarter 2025 revenue of $37.9 million, an increase of 28% compared to the first quarter of 2024, reflecting: The sale of 27,579 Light Adjustable Lenses (LAL®/LAL+®), representing a 36% increase in procedure volume compared to the first quarter of 2024;The sale of 73 Light Delivery Devices (LDD™s), bringing the installed base to 1,044 LDDs as of M

      5/7/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. to Report First Quarter 2025 Financial Results on May 7, 2025

      ALISO VIEJO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the first quarter of 2025 after the market close on Wednesday, May 7, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 8740296. The call will also be broadcast live in listen-only mode via a link on the company's investor relations web

      4/23/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance

      ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary revenue results for the first quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Thursday, April 3, 2025, at 8:00 a.m. Eastern Time. Preliminary First Quarter 2025 Results Preliminary first quarter 2025 revenue is expected to be approximately $37.9 million, representing growth of 28% compared to the prior year period, and a decrease of 6% compared to the fourth quarter of 2024, driven by: The sale

      4/2/25 8:00:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RxSight upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded RxSight from Equal Weight to Overweight and set a new price target of $25.00

      5/19/25 8:47:30 AM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Piper Sandler initiated coverage on RxSight with a new price target

      Piper Sandler initiated coverage of RxSight with a rating of Neutral and set a new price target of $18.00

      4/15/25 9:02:26 AM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight downgraded by UBS with a new price target

      UBS downgraded RxSight from Buy to Neutral and set a new price target of $16.00

      4/9/25 8:36:59 AM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    SEC Filings

    See more
    • SEC Form SD filed by RxSight Inc.

      SD - RxSight, Inc. (0001111485) (Filer)

      5/20/25 4:30:10 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form 10-Q filed by RxSight Inc.

      10-Q - RxSight, Inc. (0001111485) (Filer)

      5/7/25 4:15:25 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - RxSight, Inc. (0001111485) (Filer)

      5/7/25 4:10:09 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by RxSight Inc.

      SC 13G/A - RxSight, Inc. (0001111485) (Subject)

      11/14/24 5:46:12 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RxSight Inc.

      SC 13G/A - RxSight, Inc. (0001111485) (Subject)

      11/12/24 4:50:57 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RxSight Inc.

      SC 13G/A - RxSight, Inc. (0001111485) (Subject)

      11/12/24 9:40:27 AM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Thunen Shelley B exercised 7,792 shares at a strike of $4.34, increasing direct ownership by 25% to 38,354 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      4/15/25 8:57:36 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Director Fountain Tamara sold $180,002 worth of shares (7,000 units at $25.71), decreasing direct ownership by 22% to 24,793 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      3/13/25 4:46:51 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form 4 filed by Officer Weinberg Eric

      4 - RxSight, Inc. (0001111485) (Issuer)

      2/27/25 8:06:48 PM ET
      $RXST
      Ophthalmic Goods
      Health Care